Drug Interaction Report
1 drug interaction and 3 additional warnings found for the following 2 drugs:
- lonafarnib
- trofinetide
Drug interactions
Minor drug interactions
Minor:lonafarnib trofinetide
Applies to: lonafarnib, trofinetide
Information for this minor interaction is available on the professional version.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:Food/Lifestyle lonafarnib
Applies to: lonafarnib
Consuming grapefruit, grapefruit juice, grapefruit hybrids, starfruit, and Seville oranges (also known as bitter or sour oranges) during treatment with lonafarnib is not recommended. Doing so may significantly increase the blood levels and effects of lonafarnib.
This may increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening.
You may be more susceptible if you have:
- a heart condition called congenital long QT syndrome
- other cardiac diseases
- conduction abnormalities
- electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting)
The risk and/or severity of other side effects may also increase, including:
- nausea
- vomiting
- diarrhea
- loss of appetite
- electrolyte (e.G., calcium, magnesium, potassium, phosphate, sodium) abnormalities
- liver problems
- low red and white blood cell counts
- infection
- high blood pressure
Additionally, you should take lonafarnib with the morning and evening meals and an adequate amount of water.
You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment.
Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
2 potential interactionsApplies to: 2 conditions, including Liver Disease and Renal Dysfunction.
Liver Disease
Moderate:lonafarnib
Lonafarnib has a moderate potential interaction with Liver Disease.
Hepatic transaminase elevations (i.e., aspartate aminotransferase AST] and alanine aminotransferase ([ALT]) have been reported during lonafarnib therapy. Often these elevations improve with continued therapy, but it is not possible to exclude this drug as a cause of the abnormalities. Liver enzymes should be monitored periodically during therapy.
Renal Dysfunction
Moderate:lonafarnib
Lonafarnib has a moderate potential interaction with Renal Dysfunction.
Lonafarnib has not been studied in patients with renal impairment, however, this drug caused nephrotoxicity in rats at plasma drug exposures approximately equal to that achieved with the human dose. Renal function should be monitored at regular intervals during therapy.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.